Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 93003344
Fax: (61-2) 92216333
Website: www.biotron.com.au

29 April 2021
The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000
(2 pages by email)
Dear Madam

## R\&D Tax Incentive

Biotron Limited (ASX: BIT) is pleased to announce that it has received an R\&D Tax Incentive refund of $\$ 1,411,944$ R\&D Tax Incentive refund for the 2019/20 financial year.

The R\&D Tax Incentive is an Australian Government program under which companies receive cash refunds for $43.5 \%$ of eligible expenditure on research and development.

The incentive refund results from expenditure on Biotron's antiviral drug development programs.
Biotron's Managing Director, Dr Michelle Miller commented: "Whilst Biotron is fully funded for its current activities, this R\&D cash rebate will strengthen the Company's cash position and support commercialisation activities."

Yours sincerely


Peter J. Nightingale
Company Secretary
pjn10758


#### Abstract

About Biotron Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and promising preclinical programs for SARS-CoV-2 and Hepatitis B Virus. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.


## Enquiries

Dr Michelle Miller
Managing Director
Rudi Michelson
Biotron Limited
Monsoon Communications
+61-(0)412313329
+61-3 96203333

This announcement has been approved by the Company's Managing Director.

